IL17A and psoriasis: Since topical and systemic therapies could induce SPRY1 to reappear in the recovered psoriatic epidermis, we examined SPRY1 in relapsed skin from moderate‐to‐severe psoriasis patients treated with efalizumab (anti‐CD11a, Raptiva, from GDS4606, n = 4), adalimumab (anti‐tumour necrosis factor‐α [TNFα], Humira, our patient) and secukinumab (anti‐IL17, Cosentyx, our patient).